EODData

SHE, 300685: Amoy Diagnostics Co Ltd

26 Nov 2025
LAST:

22.02

CHANGE:
 0.11
OPEN:
22.14
HIGH:
22.42
ASK:
0.00
VOLUME:
3.15M
CHG(%):
0.50
PREV:
22.13
LOW:
22.02
BID:
0.00
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Nov 2522.1422.4222.0222.023.15M
25 Nov 2521.7122.2721.6622.135.3M
24 Nov 2521.4521.7721.4021.653.19M
21 Nov 2522.0022.2021.4021.406.23M
20 Nov 2522.5022.5822.0522.074.23M
19 Nov 2522.9022.9722.3622.405.5M
18 Nov 2523.2823.3022.8122.886.48M
17 Nov 2523.8123.9023.1923.307.81M
14 Nov 2523.6124.1323.6023.798.11M
13 Nov 2523.8223.8223.5323.757.43M

PROFILE

Name:Amoy Diagnostics Co Ltd
About:Amoy Diagnostics Co., Ltd. engages in the development and commercialization of diagnostics product for oncology in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers, and advances targeted treatment research in ovarian cancer; AmoyDx HRD complete panel, detects genetic aberrations across HRR genes and HRD status; AmoyDx master panel, a CGP assay; AmoyDx BRCA Pro panel, covers various protein coding regions, intron/exon boundaries, select introns, and UTR regions of the BRCA1 and BRCA2 genes; AmoyDx handle classic NGS panel, detects multiple gene mutations in cancer patients for treatment; and AmoyDx essential NGS panel, detects EGFR, ALK, ROS1, RET, KRAS, NRAS, PIK3CA, BRAF, HER2, and MET genes in patients with non-small cell lung cancer and colorectal cancer using FFPE or liquid biopsy samples. It also provides AmoyDx handle HRR NGS panel for detection of somatic and germline variants; AmoyDx pan lung cancer PCR panel, a tissue-based real-time qPCR assay for in vitro diagnostics; AmoyDx myeloid blood cancer panel; AmoyDx comprehensive panel, a sequencing-based test capable of detecting a range of alterations; AmoyDx PD-L1 (E1L3N) assay; and AmoyDx handle melanoma NGS panel, detects single nucleotide variants, insertions, and deletions within pivotal melanoma tumor genes. In addition, the company offers ALK gene fusions and ROS1 gene fusions, multi-gene mutations, EML4-ALK fusion gene, EGFR/ALK/ROS1 mutations, MET mutation, HER2 mutation, RET gene fusions, KRAS mutation, KRAS/NRAS mutations, NRAS mutation, KRAS/NRAS/BRAF mutations, BRAF mutation, PIK3CA five mutations, microsatellite instability, PIK3CA mutation, human papillomavirus genotyping, JAK2 mutation, TERT/HRAS mutations, EGFR 29 mutations, EGFR mutation, ROS1 gene fusions, NTRK gene fusions, BRAF V600 mutations detection kits, as well as DNA and RNA extraction kits under the Super-ARMS and AmoyDx names. The company was founded in 2008 and is ba
Sector:Healthcare
Address:No. 39 Dingshan Road, Xiamen, China, 361027
Website:https://www.amoydx.com
ISIN:CNE1000034D3

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:31.23 
Forward P/E:23.82 
PEG Ratio:23.82 
Price to Sales:8.03 
Price to Book:4.57 
Profit Margin:0.26 
Operating Margin:0.21 
Return on Assets:0.08 
Return on Equity:0.15 
DivYield:0.01 
Div/Share:0.30 
Revenue:1.127B 
EBITDA:377.24M 
Shares:391.54M 
Market Cap:8.622B 

TECHNICAL INDICATORS

MA5:21.850.8%
MA10:22.542.4%
MA20:22.853.8%
MA50:22.954.2%
MA100:23.325.9%
MA200:22.662.9%
STO9:22.71
STO14:22.71
RSI14:37.62 
WPR14:-74.38
MTM14:-1.16
ROC14:-0.05 
ATR:0.51 
Week High:22.974.3%
Week Low:21.402.9%
Month High:24.139.6%
Month Low:21.402.9%
Year High:27.1723.4%
Year Low:19.2714.3%

RECENT SPLITS

Date Ratio
31 May 20221-1
16 Jun 20201-1
28 Jun 20181-1

RECENT DIVIDENDS

Date Amount
03 Jun 2025$0.30
30 May 2024$0.15
23 May 2023$0.14
31 May 2022$0.23
09 Jun 2021$0.14
16 Jun 2020$0.14
21 May 2019$0.07